Myotech CSS Data to Be Presented at Annual Meeting of the American Society of Artificial Internal Organs

PITTSFORD, NY, Jun 19 (MARKET WIRE) --
Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation
biomedical technology, today announced a presentation of animal study
data on the Myotech Circulatory Support System (CSS) at the 54th annual
meeting of the American Society of Artificial Internal Organs (ASAIO) in
San Francisco, June 19th - 21st. The data to be presented confirm the
effectiveness of the Myotech CSS in supporting whole heart function in a
manner not possible with other known systems, and also highlights the
value of ultrasound imaging as an adjunct to the CSS.

The Myotech CSS consists of a flexible polymer cup that slips over the
heart and connects to an external drive unit to pump the heart and restore
normal blood flow. It can be installed in approximately three minutes
through a small incision to provide immediate, life-saving support in
emergency situations. Since it has no contact with circulating blood, the
Myotech CSS is expected to reduce the risk of patient complications, such
as clotting and stroke, bleeding, and infection.

In the poster presentation, Myotech Medical Director Mark Anstadt M.D. and
his colleagues at Wright State University will show recent data from
animal studies where an ultrasound technique called Velocity Vector
Imaging (VVI) is used to image the position of the cup on the heart, but
also the speed of movement of every section of cardiac tissue, while the
heart is being supported by the CSS device. These data clearly indicate
the superior performance of the CSS during the critical diastolic
(filling) part of the cardiac cycle. Conventional ventricular assist
devices cannot provide this level of support for a damaged or failing
heart.

The first generation Myotech CSS system is being developed for acute heart
failure applications using VVI and other ultrasound methods to refine the
design and control of the CSS cup. Future generations of the product may
have partially integrated ultrasound capability, making the system easier
to optimize for each patient.

"This study supports our expectations regarding the superior performance
of the Myotech CSS in providing natural circulatory support under a
variety of emergency situations," stated John Lanzafame, Biophan CEO.
"Our initial focus is on acute resuscitation, which will be the initial
application of the technology. This study demonstrates that the Myotech
CSS augments diastolic function unlike other known devices, which is
important in short-term support, but also may be very helpful in
longer-term support situations. We are very excited about the potential
of this technology platform."

About Biophan Technologies, Inc.

Biophan is dedicated to providing technologies that offer innovative and
competitive advantages to the medical device industry. The Company is
helping to commercialize the Myotech Circulatory Support System, which has
significant potential to improve the treatment of acute heart failure.
Biophan Technologies, Inc. holds a 68% interest in Myotech with rights to
acquire additional equity, and is leading Myotech's business development
efforts. Biophan is traded on the OTC market under the symbol BIPH, and is
also listed on the Frankfurt Stock Exchange under the symbol BTN. For more
information on Biophan, please visit our website at www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute
forward-looking statements within the meaning of applicable securities
laws. These statements reflect what Biophan anticipates, expects, or
believes may happen in the future. Biophan's actual results could differ
materially from the outcome or circumstance expressed or implied by such
forward-looking statements as a result of a variety of factors including,
but not limited to: Biophan's ability to develop its technologies; the
approval of Biophan's patent applications; the successful implementation
of Biophan's research and development programs; the ability of Biophan to
demonstrate the effectiveness of its technology, generally, and in human
patients; the acceptance by the market of Biophan's technology and
products incorporating such technology; the ability of Biophan to
effectively negotiate and enter into contracts with medical device
manufacturers for the licensing of Biophan's technology; competition; the
ability of Biophan to raise capital to fund its operating and research
and development activities until it generates revenues sufficient to do
so; and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in
Biophan's periodic filings with the Securities and Exchange Commission
(the "SEC"). As a result, this press release should be read in
conjunction with Biophan's periodic filings with the SEC, which are
incorporated herein by reference. The forward-looking statements
contained herein are made only as of the date of this press release, and
Biophan undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.

Contact:
Carolyn Hotchkiss
Communications Manager
Biophan Technologies, Inc.
(585) 267-4800
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-